CCCC in the 13F filings
C4 Therapeutics Inc · CUSIP 12529R107
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 15 May 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 1 listed it in both
- Shares listed
- 16,682,928
- combined, among listed positions
- Reported value
- $44m
- combined, at the quarter end
Among the 91 comparable managers: 14 buyers (opened or added shares) and 7 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -2,603,381.
Managers listing CCCC in Q1 2026
22 of 22 holders
Largest increases and reductions, by shares
Increases
- Citadel Advisors LLCexisting position · 2,511,015 shares now+2,063,207
- Two Sigma Investments LPexisting position · 3,035,634 shares now+1,526,031
- Acadian Asset Management LLCexisting position · 1,890,914 shares now+1,233,741
- D. E. Shaw & Co.existing position · 1,060,331 shares now+1,007,452
- Renaissance Technologies LLCexisting position · 2,461,815 shares now+859,235
Reductions
- Point72 Asset Management LPexisting position · 169,096 shares now-9,270,232
- Susquehanna International Group LLPexisting position · 1,286,840 shares now-488,943
- Walleye Capital LLCexisting position · 239,118 shares now-204,223
- Marshall Wace LLPexisting position · 155,495 shares now-109,532
- Squarepoint Ops LLCexisting position · 40,664 shares now-95,390
New positions and exits
New (3)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 1 | $5.5m | n.a. | n.a. |
| Q1 2021 | 1 | $2.0m | n.a. | n.a. |
| Q2 2021 | 1 | $981k | n.a. | n.a. |
| Q4 2021 | 1 | $2.6m | n.a. | n.a. |
| Q1 2022 | 1 | $12m | n.a. | n.a. |
| Q2 2022 | 2 | $3.2m | n.a. | n.a. |
| Q4 2022 | 1 | $338k | n.a. | n.a. |
| Q1 2023 | 2 | $369k | n.a. | n.a. |
| Q2 2023 | 1 | $73k | n.a. | n.a. |
| Q1 2024 | 2 | $401k | 2 | 0 |
| Q2 2024 | 2 | $226k | 0 | 0 |
| Q3 2024 | 1 | $160k | 0 | 0 |
| Q4 2024 | 2 | $177k | 0 | 0 |
| Q1 2025 | 1 | $45k | 0 | 0 |
| Q2 2025 | 1 | $40k | 0 | 0 |
| Q3 2025 | 1 | $62k | 0 | 0 |
| Q4 2025 | 1 | $53k | 16 | 2 |
| Q1 2026 | 1 | $74k | 14 | 7 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CCCC and GILD →CCCC and AMGN →CCCC and ARGX →Choose a stock to compare with CCCC →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CCCC, latest filings →Back to the 13F Explorer →